Timeline of therapeutic strategies in type 1 diabetes illustrating past, current, and emerging interventions.
<p>Historically, the clinical strategy has been metabolic management focused exclusively on exogenous insulin replacement to correct its absence after destruction of beta cells. Advances in the field have led to optimized glycemic control through advanced insulin formulations, continuous gluco...
Պահպանված է:
| Հիմնական հեղինակ: | |
|---|---|
| Այլ հեղինակներ: | , |
| Հրապարակվել է: |
2025
|
| Խորագրեր: | |
| Ցուցիչներ: |
Ավելացրեք ցուցիչ
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
| Ամփոփում: | <p>Historically, the clinical strategy has been metabolic management focused exclusively on exogenous insulin replacement to correct its absence after destruction of beta cells. Advances in the field have led to optimized glycemic control through advanced insulin formulations, continuous glucose monitoring, and automated delivery systems. Beginning in the 1980s, immunomodulatory therapies began testing, aimed at preventing or slowing the loss of beta cell function after clinical diagnosis. With the recognition that the pathogenesis occurs over years and that prediction of disease is possible, the delay in diagnosis in those at risk led to its approval in 2022. Emerging strategies include beta cell replacement, with genetic modifications of the transplanted cells, potentially in combination with a brief immune treatment, to avoid the need for chronic immune suppression, or even induction of beta cell regeneration. The long-term goal, which would require expansion of screening to the general population and the enhancement of rates and duration of responses, is to arrest disease before its presentation, as exemplified by teplizumab. Figure created in Biorender. Sydney, G. (2025) <a href="http://BioRender.com/ywgcezg" target="_blank">http://BioRender.com/ywgcezg</a>.</p> |
|---|